Phase 3 Stroke Trial, Recruiting NCT05604638 Sponsor: Second Affiliated Hospital of Guangxi Medical University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT05604638
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who received a clot-dissolving drug called tenecteplase through a drip for a stroke, and whose symptoms either stayed about the same, got worse, or fluctuated up and down significantly within 4 to 24 hours after that treatment
  • People whose stroke symptoms are at a certain level of severity (a score of 4 or more on a standard stroke assessment scale) before being assigned to a treatment group in the trial
  • People, or their family members, who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

  • People in whom bleeding inside the brain was found on a brain scan (CT or MRI) after receiving the clot-dissolving treatment
  • People whose brain scans (CTA, MRA, or DSA) show a blockage in certain major blood vessels supplying the brain (confirm with trial site for the specific vessels involved)
  • People whose stroke is confirmed or suspected to have been caused by a blood clot travelling from the heart or another source — this includes people with conditions such as atrial fibrillation, certain heart valve problems, a blood clot inside the heart, a weakened heart muscle, a hole between the upper chambers of the heart combined with a bulging wall between them, or a stroke of unknown cause with a high risk score for future clots
  • People with a low platelet count (a type of blood cell that helps with clotting) below a certain level
  • People with poor kidney function, where the kidneys are filtering blood at a rate below a certain threshold
  • People who are pregnant or breastfeeding
  • People with a known allergy to the drug tirofiban, or to nickel, titanium, or their alloys
  • People with a pre-existing brain or psychiatric condition that makes it impossible to assess how their nervous system is functioning
  • People with a pre-existing bleeding disorder, or severe disease of the heart, liver, or kidneys, or a serious blood infection (sepsis)
  • People who have a brain tumour that is pressing on surrounding brain tissue (small tumours on the brain's outer lining may be considered separately — confirm with trial site)
  • People with a brain aneurysm or an abnormal tangle of blood vessels in the brain (arteriovenous malformation)
  • People with a serious illness where life expectancy is estimated to be less than 6 months
  • People who are already taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhongming Qiu, MD, Sun Yet-sen University

Phone: +8618376635080

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Second Affiliated Hospital of Guangxi Medical University
Registry
ClinicalTrials.gov
Start date
24 April 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Excellent functional outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov